Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IL-17 targeting NanoAb - Scinai Immunotherapeutics/The Max Planck Society/University Medical Center Gottingen

Next Previous
X
Search
Drug Profile

IL-17 targeting NanoAb - Scinai Immunotherapeutics/The Max Planck Society/University Medical Center Gottingen

Alternative Names: anti-IL-17 VHH antibody; Anti-IL-17A/F NanoAbs

Latest Information Update: 25 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator The Max Planck Society; University Medical Center Gottingen
  • Developer Scinai Immunotherapeutics
  • Class Anti-inflammatories; Antibodies; Antipsoriatics; Antirheumatics; Single-domain antibodies; Skin disorder therapies
  • Mechanism of Action IL17A protein modulators; IL17F protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Atopic dermatitis; Hidradenitis suppurativa; Plaque psoriasis; Psoriatic arthritis

Most Recent Events

  • 23 Jul 2024 Scinai Immunotherapeutics received positive regulatory feedback from the Paul Erlich Institute (the PEI) of Germany for IMPD filing with the European Medicines Agency (EMA) for Plaque psoriasis
  • 23 Jul 2024 BiondVax Pharmaceuticals plans a phase I/IIa trial in Plaque Psoriasis in the second half of 2025 (Intradermal, Injection)
  • 15 Jul 2024 Pharmacodynamics data from preclinical trial in Plaque psoriasis released by Scinai Immunotherapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top